Melanoma Clinical Trial
Official title:
A Phase 1 Study of INCB099280 in Combination With Ipilimumab in Participants With Select Solid Tumors
The purpose of this study is to characterize the safety, tolerability, PK, and efficacy of INCB 99280 in combination with ipilimumab in participants with select solid tumors.
Status | Recruiting |
Enrollment | 100 |
Est. completion date | July 27, 2026 |
Est. primary completion date | June 27, 2025 |
Accepts healthy volunteers | No |
Gender | All |
Age group | 18 Years and older |
Eligibility | Inclusion Criteria: - Prior systemic therapy, diagnoses and disease setting as follows: - For Part 1 (dose escalation), and no history of treatment with anti-CTLA-4 or anti-PD-(L)1 therapy and one of the following, - Unresectable or metastatic cutaneous melanoma, or - Unresectable of metastatic Child-Pugh Class A NDD not eligible for surgical and/or locoregional therapy, or - Intermediate or poor-risk advanced clear cell RCC, or - MSI-H or dMMR metastatic CRC and able to provide fresh or archival tumor tissue for central confirmation of MSI-H or dMMR. - For Part 2 (dose expansion), IO treatment -naïve, e.g., no prior receipt of an anti PD-1, anti-PD-L1 or PD-L1, anti-CTLA-4, GITR, LAG3, TIM3, OX-40, IL-2, 4-1BB or other immune modulator, and have not received prior systemic therapy and one of the following, - Unresectable or metastatic Child-Pugh Class A HCC not eligible for surgical and/or locoregional therapy, or - Intermediate - or poor-risk advanced clear cell RCC. - ECOG performance score of 0 or 1. - Life expectancy > 3 months, in the opinion of the investigator. - Histologically confirmed solid tumors with measurable disease per RECIST v1.1. - Exception: HCC may be diagnoses based on cross-sectional multiphasic imagining using the AASLD criteria. - Willingness to avoid pregnancy or fathering children. Exclusion Criteria: - Known history of an additional malignancy. - Central nervous system (CNS) metastases requiring treatment and/or leptomeningeal disease. - Toxicity from prior therapy that has not recovered. - Received thoracic radiation within 6 months of the first dose of study treatment. - Participation in another interventional clinical study while receiving INCB099280. - Impaired cardiac function of clinically significant cardiac disease. - History of evidence of interstitial lung disease including non-infections pneumonitis. - Presence of gastrointestinal condition that may affect drug absorption - Any autoimmune disease requiring systemic treatment in the past 5 years. - Diagnosis of immunodeficiency or receiving chronic systemic steroid therapy at a daily dose exceeding 10 mg of prednisone or equivalent - Active infection requiring systemic therapy. - History of organ transplantation, including allogeneic stem cell transplantation. - Receipt of system antibiotics within 28 days of first dose of study treatment. - Probiotic usage is prohibited during the screening and throughout the study treatment period. - Received a live vaccine within 28 days of planned start of study drug. - Laboratory values outside the Protocol-defined ranges. Other protocol-defined Inclusion/Exclusion Criteria may apply. |
Country | Name | City | State |
---|---|---|---|
Canada | McGill University Health Centre/Glen Site/Cedars Cancer Centre | Montreal | Quebec |
Canada | Princess Margaret Cancer Center | Toronto | Ontario |
Mexico | Hospital Civil de Guadalajara Fray Antonio Alcalde | Guadalajara | |
South Africa | Johese Clinical Research: Midstream | Centurion | |
South Africa | Mary Potter Oncology Centre | Pretoria | |
United States | University of North Carolina At Chapel Hill | Chapel Hill | North Carolina |
United States | Henry Ford Health System | Detroit | Michigan |
United States | Alliance For Multispecialty Research Llc | Knoxville | Tennessee |
United States | Valkyrie Clinical Trials | Los Angeles | California |
United States | UC Irvine Medical Center | Orange | California |
United States | Sharp Memorial Hospital | San Diego | California |
Lead Sponsor | Collaborator |
---|---|
Incyte Corporation |
United States, Canada, Mexico, South Africa,
Type | Measure | Description | Time frame | Safety issue |
---|---|---|---|---|
Primary | Occurence of DLTs | 2 Years | ||
Primary | Incidence of TEAEs | Assessed by physical examinations, changes in vital signs and ECGs, and analysis of clinical laboratory samples. | 2 Years | |
Primary | Incidence of TEAEs leading to dose interruption, dose reduction, or discontinuation of either of the study drugs | 2 Years | ||
Secondary | Concentration of INCB099280 in plasma | 2 Years | ||
Secondary | Objective response | Defined as having a best overall response of complete response or partial response by investigator assessment per RECIST v1.1. | 2 Years | |
Secondary | Disease control | Defined as having a best overall response of complete response or partial response, or stable disease of = 15 weeks after initiation of study treatment, by investigator assessment per RECIST v1.1. | 2 Years | |
Secondary | Duration of Response | Defined as the time from the earliest date of CR or PR until the earliest date of disease progression (by investigator assessment per RECIST v1.1) or death due to any cause if occurring sooner than progression. | 2 Years |
Status | Clinical Trial | Phase | |
---|---|---|---|
Recruiting |
NCT05094804 -
A Study of OR2805, a Monoclonal Antibody Targeting CD163, Alone and in Combination With Anticancer Agents
|
Phase 1/Phase 2 | |
Completed |
NCT03979872 -
Risk Information and Skin-cancer Education for Undergraduate Prevention
|
N/A | |
Recruiting |
NCT04986748 -
Using QPOP to Predict Treatment for Sarcomas and Melanomas
|
||
Enrolling by invitation |
NCT00068003 -
Harvesting Cells for Experimental Cancer Treatments
|
||
Recruiting |
NCT05707286 -
Pilot Study to Determine Pro-Inflammatory Cytokine Kinetics During Immune Checkpoint Inhibitor Therapy
|
||
Active, not recruiting |
NCT05470283 -
Phase I, Open-Label, Study of Tumor Infiltrating Lymphocytes Engineered With Membrane Bound IL15 Plus Acetazolamide in Adult Patients With Metastatic Melanoma
|
Phase 1 | |
Recruiting |
NCT05077137 -
A Feasibility Study Utilizing Immune Recall to Increase Response to Checkpoint Therapy
|
Phase 1 | |
Active, not recruiting |
NCT02721459 -
XL888 + Vemurafenib + Cobimetinib for Unresectable BRAF Mutated Stage III/IV Melanoma
|
Phase 1 | |
Completed |
NCT00341939 -
Retrospective Analysis of a Drug-Metabolizing Genotype in Cancer Patients and Correlation With Pharmacokinetic and Pharmacodynamics Data
|
||
Recruiting |
NCT05839912 -
Excision of Lymph Node Trial (EXCILYNT) (Mel69)
|
N/A | |
Recruiting |
NCT04971499 -
A Study of Dapansutrile Plus Pembrolizumab in Patients With PD-1 Refractory Advanced Melanoma
|
Phase 1/Phase 2 | |
Recruiting |
NCT05263453 -
HL-085+Vemurafenib to Treat Advanced Melanoma Patients With BRAF V600E/K Mutation
|
Phase 2 | |
Active, not recruiting |
NCT05060432 -
Study of EOS-448 With Standard of Care and/or Investigational Therapies in Participants With Advanced Solid Tumors
|
Phase 1/Phase 2 | |
Not yet recruiting |
NCT06413680 -
A First-In Human (FIH) Trial to Find Out if REGN10597 is Safe and How Well it Works for Adult Participants With Advanced Solid Organ Malignancies
|
Phase 1/Phase 2 | |
Completed |
NCT03348891 -
TNF in Melanoma Patients Treated With Immunotherapy
|
N/A | |
Terminated |
NCT03399448 -
NY-ESO-1-redirected CRISPR (TCRendo and PD1) Edited T Cells (NYCE T Cells)
|
Phase 1 | |
Completed |
NCT03171064 -
Exercise as a Supportive Measure for Patients Undergoing Checkpoint-inhibitor Treatment
|
Phase 2 | |
Not yet recruiting |
NCT05539118 -
Interferon-α1b Combined With Toripalimab and Anlotinib Hydrochloride in Advanced Unresectable Melanoma
|
Phase 1/Phase 2 | |
Recruiting |
NCT05171374 -
pRospective Evaluation of Clinical Outcomes in Patients With metAsTatIс melanOma Treated With dabrafeNib and trAmetinib in reaL practicE
|
||
Withdrawn |
NCT02854488 -
Yervoy Pregnancy Surveillance Study
|